Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc.'s Chief Legal & Public Affairs Officer, Kathleen Alyce Waters, reported two open-market sales of the company’s Common Stock. On June 15, 2026, she sold a total of 15,405 shares in two transactions: 6,455 shares at a weighted average price of $209.167 per share and 8,950 shares at a weighted average price of $207.844 per share. The filing notes price ranges for each sale and that one transaction was made under a Rule 10b5-1 trading plan adopted on March 16, 2026. After these sales, Waters continues to hold over 100,000 DaVita shares directly.
DaVita Inc. Chief Executive Officer Javier Rodriguez reported selling DaVita common stock in two open-market transactions. On June 15, 2026, he sold 30,000 shares of Common Stock at a weighted average price of $209.503 per share, in a price range from $209.000 to $210.140. On June 16, 2026, he sold an additional 39,407 shares at a weighted average price of $209.278 per share, within a range of $209.200 to $209.800. Following these sales, Rodriguez directly holds 840,408 shares of DaVita common stock.
DaVita Inc. filed a Rule 144 notice indicating proposed sales of Common Stock, listing 64,200,000 shares with a filing date of 06/16/2026. The excerpt also shows 30,000 shares sold on 06/15/2026 and an Employee Stock Appreciation Right exercise dated 08/28/2024.
The filing lists broker information and sale method details for NYSE-listed common shares. Transactional and cash-proceeds treatment are not specified in the provided excerpt.
DaVita Inc. submitted a Form 144 notice reporting proposed sales of Common Stock by a reporting person and listing recent plan-related acquisitions. The filing lists an attempted sale of 6,455 shares on 06/15/2026 alongside employee-related issuances: 1,562 (stock option exercise 08/28/2024), 2,114 (restricted stock vesting 03/15/2025), and 5,274 (performance award vesting 03/15/2025).
The document names UBS Financial Services Inc. as the broker and shows an account/address for the reporting person. Holdings or further cash‑flow treatment beyond the listed items are presented as raw entries in the excerpt.
Form 144 notice: proposed sale of Common Stock related to DVA. The filing lists proposed sales tied to SAR exercises dated 11/17/2024 (1,400 shares) and 08/28/2024 (5,055 shares). The excerpt also records a sale by Kathleen Waters of 8,950 shares on 06/15/2026 for $1,860,202.07.
The filing identifies UBS Financial Services, Inc. at 11 Madison Ave as the broker-dealer line and shows a table entry with 6,455 in the securities column and a separate numeric entry of 64,200,000 shares tied to 06/15/2026. The document appears to be a routine Rule 144 notice of proposed sales rather than an operational or financial report.
DaVita Inc. entered into a Ninth Amendment to its 2019 Credit Agreement, adding an incremental $500 million in senior secured Tranche B-2 Term Loans maturing in May 2031. These loans are in U.S. dollars and bear interest at either a Base Rate plus a 75-basis-point applicable margin or Term SOFR plus a 175-basis-point applicable margin.
DaVita has used or will use the new term loan proceeds to repay a portion of its senior secured revolving loan facility terminating in November 2030, pay related fees and expenses, and for general corporate purposes. At its virtual 2026 annual meeting, stockholders representing 59,865,902 shares, about 91% of shares outstanding as of April 9, 2026, elected nine directors, ratified KPMG LLP as auditor for 2026, and approved named executive officer compensation on an advisory basis.
DaVita Inc. director Phyllis R. Yale reported a bona fide gift of 5,038 shares of DaVita common stock. The shares were transferred at no stated value per share. After this gift, she directly holds 9,525 shares, indicating she retains a meaningful ongoing equity stake in the company.
Pullin Dennis W reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Dennis W. Pullin received a grant of 250 shares of Common Stock on May 15, 2026. The shares were awarded at no stated purchase price as equity compensation. After this award, he directly holds a total of 2,671 DaVita common shares.
Moore Gregory J. reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Gregory J. Moore received 250 shares of common stock as a grant on May 15, 2026, at no cost. This compensation-related award increased his directly held stake to 7,813 shares. The transaction reflects an equity grant rather than an open-market purchase or sale.